Evaluation of a Scalable Harvest Protocol Using a Panel of AAV Serotypes with Attention to Recombinant Aav Vector Integrity and Functionality

By SIRION Biotech

There is a continued effort to design more efficacious rAAV vectors, particularly ones that can be administered at lower doses.

However, several indications still require high-dose systemic administration, underscoring the importance of advancing rAAV manufacturing and upscaling processes to continue the ongoing success of rAAV applications.

To read more, please download this free white paper.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.